Trouble reading this e-mail? View it in your browser.

EFPIA
Newsletter
26 May 2016
Header
Header image
News

News

TTIP Report Study Highlights the Positive Benefits of Ambitious Pharmaceutical Provisions in the Proposed Agreement for Europe’s Economy and Society
24 May 2016

The Transatlantic Trade and Investment Partnership (TTIP) represents an obvious opportunity to improve the functioning of the transatlantic market place for pharmaceutical products, reduce unnecessary [...] Read more

News

EFPIA welcomes TTIP progress on regulatory convergence but more ambitious outcomes are expected
25 May 2016

EFPIA welcomes the publication of the European Commission’s negotiating proposal on regulatory cooperation in pharmaceuticals, and its efforts to increase transparency in the TTIP negotiations.  [...] Read more

From our blog

From our blog

It’s the data, stupid! How Real World Data and health outcomes can revolutionise pharmaceutical development and healthcare systems
26 May 2016 by Thomas Allvin

No other item of healthcare expenditure has been so thoroughly assessed when it comes to safety, effect and performance as pharmaceutical products. For decades, the clinical trial has been the gold standard of measuring these attributes, and indirectly the value, of pharmaceuticals.

Read more

Videos

Video

TTIP: What's in it for patients?

The Transatlantic Trade and Investment Partnership (TTIP) aims to create more open trade between the EU and the US. Strengthening the world’s most important trading relationship can serve as a key platform to bring quicker new treatment options to patients. TTIP has the potential to facilitate the development of new medicines and deliver better and faster health outcomes to patients.

Researching and developing medicines is an increasingly collaborative and global process: pharmaceutical companies, academic institutions and healthcare systems from all over the world work together to develop new and innovative medicines. By reducing the need to do things twice, TTIP can help them stimulate, drive and deliver the treatments that patients need, not only in Europe and the US but also worldwide.

View video

Events calendar

Events Calendar

EFPIA Annual Conference 2016
On 15/06/2016 (Radisson Hotel, Brussels)

This year's EFPIA Annual Conference will take place on 15 June 2016, at the Radisson Hotel in Brussels. The event will examine the challenges faced by healthcare systems in Europe, the exciting science that will play a key role in meeting these challenges and the long-term sustainability of healthcare delivery. An interactive exhibition will be set up to provide attendees with further insight into EFPIA’s current initiatives, which aim at facilitating a pan-European dialogue on the importance of shifting towards a model of outcomes-driven healthcare.
 
The final programme can be accessed here
 
Read more

Events Calendar

EudraVigilance Information Day
On 21/06/2016 (London, UK)

This EudraVigilance Information Day provides a forum to update stakeholders about the latest developments with regard to EudraVigilance in the context of the implementation of the pharmacovigilance legislation. It further aims to facilitate change management as part of the European Medicines Agency’s pharmacovigilance programme and the planning of modifications to business processes by medicines regulatory authorities and pharmaceutical companies.

Read more

Documents

From our blog

How a Strong Pharmaceutical Chapter in TTIP will Benefit the EU
24 May 2016 (Publications)

An ambitious pharmaceutical chapter in TTIP that aligns regulatory regimes and reduces duplicative costs will increase EU export of pharmaceuticals by €9 billion and provide [...] Read more

What we are reading

What we are reading

When the drugs don’t work
26 May 2016 (The Economist)

Some people describe Darwinian evolution as “only a theory”. Try explaining that to the friends and relatives of the 700,000 people killed each year by drug-resistant infections. Resistance to antimicrobial medicines, such as antibiotics and antimalarials, is caused by the survival of the fittest. 

Read more

About EFPIA updates
Unsubscribe to be removed from this mailing list | Update your subscription

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 34 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
Leopold Plaza Building
Rue du Trône 108
B-1050 Brussels (Belgium)
Tel: +32 (0)2 626 25 55
E-mail: communications@efpia.eu
Follow EFPIA
Twitter LinkedIn Youtube Google + Pinterest E-mail